Coeliac disease re-screening among once seronegative at-risk relatives: A long-term follow-up study

Saana Paavola, Kalle Kurppa, Heini Huhtala, Päivi Saavalainen, Katri Lindfors, Katri Kaukinen, Saana Paavola, Kalle Kurppa, Heini Huhtala, Päivi Saavalainen, Katri Lindfors, Katri Kaukinen

Abstract

Background: Serological screening of the relatives of coeliac disease patients is widely endorsed. However, the need for and the optimal timing of possible re-testing of once seronegative at-risk individuals for coeliac disease remain unclear.

Objective: We investigated this issue by inviting a large cohort of previously screening-negative relatives of patients with coeliac disease to participate in a follow-up study.

Methods: Altogether 599 relatives of coeliac disease index patients not diagnosed with coeliac disease in a screening study carried out in 2006-2010 were asked about possible later diagnosis or re-tested with coeliac disease autoantibodies in 2017-2021. Besides incidence, the possible impact of various patient-related clinical factors and HLA haplotype on the later diagnosis or screening positivity was examined.

Results: Fifteen (2.5%) relatives were either diagnosed with a coeliac disease (n = 8) during the follow-up period or were found to be screening-positive in the re-testing (n = 7), giving a combined annual incidence of 221/100,000 person-years in all relatives and 336/100,000 among those carrying coeliac disease-associated HLA DQ2/DQ8. The new cases more often carried the high-risk (DQ2.5/2.5 or DQ2.5/2.2; 35.7% vs. 7.4%, respectively, p < 0.001) HLA and were younger at initial screening (23.3 vs. 40.5 years, p = 0.028) and - in spite of a negative screening outcome - had higher median transglutaminase antibody level in the first study than those not affected. There were no significant differences between the affected and non-affected relatives in other demographic data, degree of kinship with the index, current symptoms or frequency of chronic co-morbidities.

Conclusion: The incidence rate for later coeliac disease diagnosis or new seropositivity in relatives who had been tested once was 221/100,000 person-years in all and 336/100,000 among those carrying at-risk HLA genetics after ∼10 years of follow-up. HLA-typing could help to target a subgroup of relatives who would benefit most from re-testing.

Trial registration: ClinicalTrials.gov NCT03136731.

Keywords: HLA; coeliac disease; genetics; gluten; kinship; serology; testing.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study

References

    1. Kårhus LL, Skaaby T, Petersen J, Madsen AL, Thuesen BH, Schwarz P, et al. Long‐term consequences of undiagnosed celiac seropositivity. Am J Gastroenterol. 2020;115(10):1681–1688. 10.14309/ajg.0000000000000737
    1. Mustalahti K, Collin P, Sievänen H, Salmi J, Mäki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet. 1999;354(9180):744–745. 10.1016/s0140-6736(99)01990-x
    1. Husby S, Koletzko S, Korponay‐Szabó IR, Mearin M, Phillips A, Shamir R, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–160. 10.1097/mpg.0b013e31821a23d0
    1. Rubio‐Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. American college of gastroenterology clinical guideline: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–677. 10.1038/ajg.2013.79
    1. Singh P, Arora S, Lal S, Strand TA, Makharia GK. Risk of celiac disease in the first‐ and second‐degree relatives of patients with celiac disease: a systematic review and meta‐analysis. Am J Gastroenterol. 2015;110(11):1539–1548. 10.1038/ajg.2015.296
    1. Paavola S, Lindfors K, Kivelä L, Cerqueira J, Huhtala H, Saavalainen P, et al. Presence of high‐risk HLA genotype is the most important individual risk factor for coeliac disease among at‐risk relatives. Aliment Pharmacol Ther. 2021;54(6):805–813. 10.1111/apt.16534
    1. Paavola S, Kaukinen K, Kurppa K. Editorial: coeliac disease‐it's a family affair. Authors' reply. Aliment Pharmacol Ther. 2021;54(7):969. 10.1111/apt.16584
    1. Vilppula A, Kaukinen K, Luostarinen L, Krekela I, Patrikainen H, Valve R, et al. Increasing prevalence and high incidence of celiac disease in elderly people: a population‐based study. BMC Gastroenterol. 2009;9(1):49. 10.1186/1471-230x-9-49
    1. Hagopian W, Lee HS, Liu E, Rewers M, She JX, Ziegler AG, et al. Co‐occurrence of type 1 diabetes and celiac disease autoimmunity. Pediatrics. 2017;140(5):e20171305. 10.1542/peds.2017-1305
    1. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence of celiac disease among children in Finland. N Engl J Med. 2003;348(25):2517–2524. 10.1056/nejmoa021687
    1. Choung RS, Khaleghi S, Cartee AK, Marietta EV, Larson JJ, King KS, et al. Community‐based study of celiac disease autoimmunity progression in adults. Gastroenterology. 2020;158(1):151–159. 10.1053/j.gastro.2019.09.006
    1. Biagi F, Campanella J, Bianchi PI, Zanellati G, Capriglione I, Klersy C, et al. The incidence of coeliac disease in adult first degree relatives. Dig Liver Dis. 2008;40(2):97–100. 10.1016/j.dld.2007.10.004
    1. Pittschieler K, Gentili L, Niederhofer H. Onset of coeliac disease: a prospective longitudinal study. Acta Paediatr. 2003;92(10):1149–1152. 10.1111/j.1651-2227.2003.tb02475.x
    1. Laurikka P, Nurminen S, Kivelä L, Kurppa K. Extraintestinal manifestations of celiac disease: early detection for better long‐term outcomes. Nutrients. 2018;10(8):1015. 10.3390/nu10081015
    1. Furtado S, Rodrigues A, Dias S, Branco JC, Canhão H. Self‐reported low‐energy fractures and associated risk factors in people with diabetes: a national population‐based study. Diabetes Res Clin Pract. 2019;147:93–101. 10.1016/j.diabres.2018.11.015
    1. Working group set up by Finnish Medical Society Duodecim and the Finnish Gastroenterology Society . Celiac disease: current care guidelines; 2018. Available online: . accessed on 3 February 2022.
    1. Rubio‐Tapia A, Van Dyke CT, Lahr BD, Zinsmeister AR, El–Youssef M, Moore SB, et al. Predictors of family risk for celiac disease: a population‐based study. Clin Gastroenterol Hepatol. 2008;6(9):983–987. 10.1016/j.cgh.2008.04.008
    1. Monsuur AJ, deBakker PIW, Zhernakova A, Pinto D, Verduijn W, Romanos J, et al. Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. PLoS One. 2008;3(5):e2270. 10.1371/journal.pone.0002270
    1. Romanos J, Rosén A, Kumar V, Trynka G, Franke L, Szperl A, et al. Improving coeliac disease risk prediction by testing non‐HLA variants additional to HLA variants. Gut. 2014;63(3):415–422. 10.1136/gutjnl-2012-304110
    1. Virta L, Saarinen M, Kolho K‐L. Declining trend in the incidence of biopsy‐verifed coeliac disease in the adult population of Finland, 2005‐2014. Aliment Pharmacol Ther. 2017;46(11‐12):1085–1093. 10.1111/apt.14335
    1. Kivelä L, Kaukinen K, Lähdeaho M‐L, Huhtala H, Ashorn M, Ruuska T, et al. Presentation of celiac disease in Finnish children is no longer changing: a 50‐year perspective. J Pediatr. 2015;167(5):1109–1115. 10.1016/j.jpeds.2015.07.057
    1. Bonamico M, Ferri M, Mariani P, Nenna R, Thanasi E, Luparia RPL, et al. Serologic and genetic markers of celiac disease: a sequential study in the screening of first degree relatives. J Pediatr Gastroenterol Nutr. 2006;42(2):150–154. 10.1097/01.mpg.0000189337.08139.83
    1. Wessels MMS, de Rooij N, Roovers L, Verhage J, de Vries W, Mearin ML. Towards an individual screening strategy for first‐degree relatives of celiac patients. Eur J Pediatr. 2018;177(11):1585–1592. 10.1007/s00431-018-3199-6
    1. Goldberg D, Kryszak D, Fasano A, Green P. Screening for celiac disease in family members: is follow‐up testing necessary? Dig Dis Sci. 2007;52(4):1082–1086. 10.1007/s10620-006-9518-1
    1. Uenishi RH, Gandolfi L, Almeida LM, Fritsch PM, Almeida FC, Nobrega YKM, et al. Screening for celiac disease in 1st degree relatives: a 10‐year follow‐up study. BMC Gastroenterol. 2014;14(1):36. 10.1186/1471-230x-14-36
    1. Högberg L, Fälth‐Magnusson K, Grodzinsky E, Stenhammar L. Familial prevalence of coeliac disease: a twenty‐year follow‐up study. Scand J Gastroenterol. 2003;38(1):61–65. 10.1080/00365520310000456
    1. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, et al. Prevalence of celiac disease in at‐risk and not‐at‐risk groups in United States: a large multicenter study. Arch Intern Med. 2003;163(3):286–292. 10.1001/archinte.163.3.286
    1. Schneider CV, Kleinjans M, Fromme M, Schneider KM, Strnad P. Phenome‐wide association study in adult coeliac disease: role of HLA subtype. Aliment Pharmacol Ther. 2021;53:510–518.
    1. Roth R, Lynch K, Lernmark B, Baxter J, Simell T, Smith L, et al. Maternal anxiety about a child's diabetes risk in the environmental determinant of diabetes in the young (TEDDY) study: the Potential role of life stress, postpartum depression and risk perception. Pediatr Diabetes. 2015;16(4):287–298. 10.1111/pedi.12168
    1. Kivelä L, Kurppa K. Screening for coeliac disease in children. Acta Paediatr. 2018;107(11):1879–1887. 10.1111/apa.14468
    1. Therrien A, Leffler DA. Editorial: coeliac disease ‐it's a family affair. Aliment Pharmacol Ther. 2021;54(7):967–968. 10.1111/apt.16552
    1. Pham‐Short A, Donaghue KC, Ambler G, Phelan H, Twigg S, Craig ME. Screening for celiac disease in type 1 diabetes: a systematic review. Pediatrics. 2015;136:e170–e176. 10.1542/peds.2014-2883
    1. Kurppa K, Paavola A, Collin P, Sievanen H, Laurila K, Huhtala H, et al. Benefits of a gluten‐free diet for asymptomatic patients with serologic markers of celiac disease. Gastroenterology. 2014;147(3):610–617. 10.1053/j.gastro.2014.05.003
    1. Mariné M, Fernández‐Bañares F, Alsina M, Farre C, Cortijo M, Santaolalla R, et al. Impact of mass screening for gluten‐sensitive enteropathy in working population. World J Gastroenterol. 2009;15(11):1331–1338. 10.3748/wjg.15.1331
    1. Schiepatti A, Savioli J, Vernero M, Borrelli de Andreis F, Perfetti L, Meriggi A, et al. Pitfalls in the diagnosis of coeliac disease and gluten‐related disorders. Nutrients. 2020;12(6):1711. 10.3390/nu12061711

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi